BELLUS Health (NASDAQ:BLU) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of BELLUS Health (NASDAQ:BLUGet Rating) from a hold rating to a buy rating in a research report report published on Tuesday morning, Zacks.com reports. They currently have $9.50 target price on the stock.

According to Zacks, “BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs. “

Separately, HC Wainwright lifted their price target on BELLUS Health from $14.00 to $16.00 and gave the company a buy rating in a research note on Thursday, February 24th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, BELLUS Health has a consensus rating of Buy and an average target price of $14.90.

BELLUS Health stock opened at $8.80 on Tuesday. BELLUS Health has a 12-month low of $2.60 and a 12-month high of $9.84. The business’s 50-day moving average price is $7.49 and its two-hundred day moving average price is $6.95. The stock has a market cap of $939.35 million, a PE ratio of -10.60 and a beta of 0.19.

BELLUS Health (NASDAQ:BLUGet Rating) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. BELLUS Health had a negative return on equity of 35.61% and a negative net margin of 436,406.25%. Research analysts forecast that BELLUS Health will post -0.77 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of BLU. Alps Advisors Inc. bought a new stake in BELLUS Health in the fourth quarter worth approximately $733,000. Monashee Investment Management LLC bought a new stake in BELLUS Health in the fourth quarter worth approximately $2,013,000. Jefferies Group LLC bought a new stake in BELLUS Health in the third quarter worth approximately $736,000. Tri Locum Partners LP increased its holdings in BELLUS Health by 159.1% in the third quarter. Tri Locum Partners LP now owns 972,997 shares of the company’s stock worth $5,974,000 after purchasing an additional 597,477 shares in the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in BELLUS Health by 51.4% in the third quarter. Rockefeller Capital Management L.P. now owns 300,000 shares of the company’s stock worth $1,842,000 after purchasing an additional 101,851 shares in the last quarter. 85.41% of the stock is currently owned by institutional investors.

BELLUS Health Company Profile (Get Rating)

BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.

Further Reading

Get a free copy of the Zacks research report on BELLUS Health (BLU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BELLUS Health (NASDAQ:BLU)

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.